These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7769868)

  • 21. Visceral leishmaniasis in patients with AIDS: report of three cases treated with pentavalent antimony and interferon-gamma.
    de Górgolas M; Castrillo JM; Fernández Guerrero ML
    Clin Infect Dis; 1993 Jul; 17(1):56-58. PubMed ID: 8353246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatitis associated with N-methyl-glucamine therapy in a dog with leishmaniasis.
    Aste G; Di Tommaso M; Steiner JM; Williams DA; Boari A
    Vet Res Commun; 2005 Aug; 29 Suppl 2():269-72. PubMed ID: 16244972
    [No Abstract]   [Full Text] [Related]  

  • 23. The irreplaceable image: Acute toxicity in erythroid bone marrow progenitors after antimonial therapy.
    Hernández JA; Navarro JT; Force L
    Haematologica; 2001 Dec; 86(12):1319. PubMed ID: 11726328
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of three chemotherapeutic schemes with meglumine antimoniate in the treatment of visceral leishmaniasis in the State of Pará, Brazil.
    Marsden PD
    Rev Inst Med Trop Sao Paulo; 1993; 35(6):589. PubMed ID: 7997767
    [No Abstract]   [Full Text] [Related]  

  • 25. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil.
    Oliveira AL; Brustoloni YM; Fernandes TD; Dorval ME; Cunha RV; Bóia MN
    Trop Doct; 2009 Jul; 39(3):180-2. PubMed ID: 19535762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Misdiagnosis of pancreatitis in patients receiving treatment with pentavalent antimonial agents.
    Laguna F; Soriano V; González-Lahoz JM
    Clin Infect Dis; 1994 Nov; 19(5):978-9. PubMed ID: 7893898
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of visceral leishmaniasis in patients with antimonials: is there a maximal dose?].
    Llorens Soriano P; Vicente Ull R; Paricio Blasco A; Cervera Juan A; Rubio Rodrigo MJ
    An Med Interna; 1999 Nov; 16(11):602. PubMed ID: 10638007
    [No Abstract]   [Full Text] [Related]  

  • 28. New delivery strategies for the old pentavalent antimonial drugs.
    Frézard F; Demicheli C
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1343-58. PubMed ID: 21029028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute erythroid toxicity in visceral leishmaniasis: a rare complication of antimonial therapy.
    Sharma S; Malhan P; Pujani M; Rath B
    Indian J Pathol Microbiol; 2008; 51(4):546-7. PubMed ID: 19008592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pancreatic toxicity of antimonials in patients with infections].
    Sánchez LA; Ferrero OL; Zubero Z; Teira R; Muñoz J; Baraia-Etxaburu J; Santamaría JM
    Rev Esp Enferm Dig; 2000 Nov; 92(11):765-6. PubMed ID: 11468860
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
    Tamiru A; Mohammed R; Atnafu S; Medhin G; Hailu A
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009713. PubMed ID: 34464401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate.
    Halim MA; Alfurayh O; Kalin ME; Dammas S; al-Eisa A; Damanhouri G
    Clin Infect Dis; 1993 Mar; 16(3):397-9. PubMed ID: 8135901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimony-induced cerebellar ataxia.
    Khalil EA; Ahmed AE; Musa AM; Hussein MH
    Saudi Med J; 2006 Jan; 27(1):90-2. PubMed ID: 16432602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leishmaniasis.
    Evans TG
    Infect Dis Clin North Am; 1993 Sep; 7(3):527-46. PubMed ID: 8254158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for acute kidney injury in visceral leishmaniasis (Kala-Azar).
    Oliveira MJ; Silva Júnior GB; Abreu KL; Rocha NA; Garcia AV; Franco LF; Mota RM; Libório AB; Daher EF
    Am J Trop Med Hyg; 2010 Mar; 82(3):449-53. PubMed ID: 20207871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-treatment fulminant hepatic failure in an infant with Visceral leishmaniasis: Immune injury or stibogluconate toxicity?
    Baranwal AK; Ravi RN; Singh R
    Indian J Pediatr; 2010 Jan; 77(1):107-8. PubMed ID: 19936650
    [No Abstract]   [Full Text] [Related]  

  • 38. Visceral leishmaniasis in paediatrics.
    Kafetzis DA; Maltezou HC
    Curr Opin Infect Dis; 2002 Jun; 15(3):289-94. PubMed ID: 12015464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.
    Hantson P; Léonard ED; Crutzen-Fayt MC; Léonard A; Vandercam B; Delaere B; Mahieu P
    Pharmacotherapy; 1996; 16(5):869-71. PubMed ID: 8888081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil.
    Daher EF; Fonseca PP; Gerhard ES; Leitão TM; Silva Júnior GB
    J Parasitol; 2009 Jun; 95(3):652-5. PubMed ID: 19642802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.